Mwb Reaffirms Sell Rating for Sartorius AG Amid Valuation Risks

07:48 AM EST, 01/08/2026 (MT Newswires) -- Sartorius AG's (SRT.F) "quality profile" remains intact but this is outweighed by valuation risks, political uncertainty and a slow market recovery over the short to medium term, mwb Research said Thursday, reaffirming its sell rating on the stock and 175-euro target price. "Sartorius remains a high-quality company with strong market positions, high entry barriers, and a resilient consumables business that has supported a gradual operational stabilization during FY25. However, the broader market environment remains challenging, with cautious capex behavior among pharma and biotech customers, elevated financing costs, and rising political uncertainty," the research firm noted. "While margins benefit from cost discipline and mix effects, visibility on a sustained recovery in order intake is limited. The stock continues to trade at a significant premium to peers, which appears difficult to justify given the moderate pace of recovery." Analysts also pointed out that European suppliers face structural risks posed by US industrial policy, which could result in stronger regionalization of pharmaceutical value chains over the medium term. Financial estimates for 2025 through 2027 were revised, including lower projected sales and EPS.